PSMA PET/CT for Response Assessment of 177Lu-PSMA Therapy.
In: Seminars in Nuclear Medicine, Jg. 54 (2024), Heft 1, S. 69-76
academicJournal
Zugriff:
Prostate-specific membrane antigen (PSMA) PET/CT has been widely integrated into the management of prostate cancer (PCa) patients with biochemical recurrence, is increasingly used for initial staging in high-risk patients prior to surgery or to identify candidates for PSMA-targeted radioligand therapy (RLT). To date, monitoring response in PCa patients in prospective studies remains the domain of conventional imaging, such as magnetic resonance/CT or bone scintigraphy. With the increasing use of PSMA-targeted PET/CT in PCa, however, varying criteria based on molecular imaging have been established to define progressive disease, including "PSMA PET Progression Criteria," "Response evaluation criteria in PSMA PET/CT (RECIP 1.0)" or consensus statements of respective societies. In the present review, we will discuss the current status of PSMA PET/CT for response monitoring, focusing on PSMA RLT with [ 177 Lu]Lu-labeled PSMA ligands, along with a head-to-head comparison of recently published response criteria. [ABSTRACT FROM AUTHOR]
Copyright of Seminars in Nuclear Medicine is the property of W B Saunders and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
PSMA PET/CT for Response Assessment of 177Lu-PSMA Therapy.
|
---|---|
Autor/in / Beteiligte Person: | Hartrampf, Philipp E. ; Serfling, Sebastian E. ; Michalski, Kerstin ; Buck, Andreas K. ; Werner, Rudolf A. |
Zeitschrift: | Seminars in Nuclear Medicine, Jg. 54 (2024), Heft 1, S. 69-76 |
Veröffentlichung: | 2024 |
Medientyp: | academicJournal |
ISSN: | 0001-2998 (print) |
DOI: | 10.1053/j.semnuclmed.2023.06.003 |
Sonstiges: |
|